Clinical trials: Pre-exposure Prophylaxis
Adherence to Medication Regime
Early Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention Among Female Sex Workers in Cotonou, Benin
In the last few years, early treatment of HIV-infected individuals, or "treatment as prevention (TasP), and pre-exposure prophylaxis with antiretroviral drugs among HIV-negative people at very high-risk of acquiring the infection…
- Trial name
- TasP/PrEP (NCT02237027)
- Testing
- TasP using ART regimen as per Benin guidelines, PrEP using Truvada
- Where
- Benin
- Volunteers
- 361 people, healthy volunteers welcome
- Sponsor
- CHU de Quebec-Universite Laval
Bias, Implicit, HIV
Intervention to Reduce Implicit Bias in Pharmacies
This study will follow the ADAPT-ITT model to apply the Prejudice Habit Breaking Intervention (PHBI) to pharmacists who have experience with or are willing to prescribe PrEP.
- Conditions
- Bias, Implicit, HIV, Pre-exposure Prophylaxis
- Trial name
- NCT06487351
- Testing
- The adapted PHBI, The NIH Implicit Bias course
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
HIV, Adolescent Behavior
Gender-Specific Combination HIV Prevention for Youth in High Burden Settings (MP3-Youth)
MP3 Youth is a pilot study to evaluate the feasibility and acceptability of a gender-specific combination HIV prevention package for youth (aged 15-24) in high burden settings.
- Conditions
- HIV, Adolescent Behavior, Gender
- Trial name
- MP3-Youth (NCT01571128)
- Testing
- Male-Specific Intervention Package, Female-Specific Intervention Package, Pre-Exposure Prophylaxis (Females)
- Where
- 3 sites in United States, Kenya
- Volunteers
- 1,215 people, healthy volunteers welcome
- Sponsor
- New York University
HIV Pre-exposure Prophylaxis
Optimizing PrEP Uptake for African American Women in the South by Empowering Women to Make Informed HIV Prevention and Sexual Health Choices
Pilot testing of EMPOWER, a group sexual health intervention, to increase uptake and persistence of PrEP
- Trial name
- EMPOWER (NCT07173816)
- Testing
- EMPOWER
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Georgia
HIV Infections
The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir
Although CAB LA PrEP has been proven efficacious in blinded randomized controlled clinical trials, additional research is needed to evaluate effectiveness in real world settings as well as to identify effective implementation…
- Trial name
- ImPrepCab (NCT05515770)
- Testing
- Cabotegravir Injection
- Where
- Brazil
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Evandro Chagas National Institute of Infectious Disease
Hiv
LA PrEP Impact and Cost-effectiveness (TEAMS)
This study will have three components: 1. Discrete choice experiments 2. Analysis of routine service data 3. Impact and cost-effectiveness analyses using results from 1 and 2
- Trial name
- NCT05774548
- Testing
- In-depth interviews (IDI), Focus group discussion (FGD)
- Where
- 12 sites in Thailand
- Volunteers
- 10,720 people, healthy volunteers welcome
- Sponsor
- Institute of HIV Research and Innovation Foundation, Thailand
HIV/AIDS
HIV Self-Testing to Empower Prevention Choices in Sex Workers
Transgender, male, and female sex workers are 49, 21 and 14 times as likely to be HIV-infected as other adults in the general population.
- Trial name
- NCT03426670
- Testing
- OraQuick HIV Self-Test
- Where
- Uganda
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Makerere University
Drug Interaction
Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for Pre-exposure Prophylaxis Among Transgender Men
There are currently no published studies addressing drug-drug interactions (DDI) between masculinizing hormone therapy (MHT) and pre-exposure prophylaxis (PrEP) among transgender men (TGM).
- Trial name
- NCT04593680
- Testing
- Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF)
- Where
- Thailand
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Thai Red Cross AIDS Research Centre
Pre-Exposure Prophylaxis, HIV Infections
PrEPARE: PrEP in Pregnancy, Accelerating Reach and Efficiency
This study tests strategies for improving PrEP implementation in maternal and child health clinics using a difference-in-difference approach.
- Conditions
- Pre-Exposure Prophylaxis, HIV Infections, Pregnancy Related
- Trial name
- NCT04712994
- Testing
- PrEP Optimization Interventions
- Where
- 8 sites in Kenya
- Volunteers
- 1,958 people, healthy volunteers welcome
- Sponsor
- University of Washington
Pre-Exposure Prophylaxis
Thailand HIV and Stigma Reduction Study
This project will develop a multi-component, technology-delivered intervention designed to reduce HIV and intersectional stigma and improve the use of HIV pre-exposure prophylaxis (PrEP) among HIV-negative Thai vulnerable…
- Trial name
- NCT06576648
- Testing
- Mobile Healthy Choices (mHC), Finding Respect and Ending Stigma around HIV (FRESH), Standard PrEP Counseling
- Where
- 3 sites in Thailand
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Pre-exposure Prophylaxis, HIV Infections
Project Phakama: Testing Support Strategies to Empower Young Women on PrEP in South Africa
The goal of this trial is to understand which strategies work best to support pre-exposure prophylaxis (PrEP) use among female sex workers (FSW) and adolescent girls and youth women (AGYW) in uMgungundlovu, KwaZulu-Natal, South…
- Trial name
- NCT06274060
- Testing
- Case management, Food vouchers, PrEP support buddy
- Where
- South Africa
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Human Immunodeficiency Virus Transmission
PC4PrEP: Integrating PrEP Into Primary Care
Oral pre-exposure prophylaxis (PrEP) has been proven effective in reducing HIV infection in high-risk men who have sex with men, heterosexually active women and men, and injecting drug users.
- Trial name
- PC4PrEP (NCT03617874)
- Testing
- PC4PrEP- Intervention Clinics, Standard of Care Clinics
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
COVID-19 Prevention
PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray
This is the first-in-human clinical study to see if a single dose of an investigational nasal spray made from a modified plant protein called Q-Griffithsin is safe, tolerated and acceptable for use by healthy adults 18 to 60…
- Trial name
- NCT05122260
- Testing
- Q-Griffithsin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Kenneth Palmer
Rabies
Safety and Immunogenicity of the Inactivated Rabies Vaccine RABIVAX-S Administered Intramuscularly and Intradermally
Randomized, open-label, prospective, before-and-after comparison study in the same group. Subjects suitable for the study will be randomly assigned at a ratio of 1:1 (block 4) to use the study vaccine by one of two routes of…
- Trial name
- NCT05937113
- Testing
- RABIVAX-S
- Where
- Vietnam
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Vietnam Military Medical University
Pre-Exposure Prophylaxis, HIV
PrEPTECH Phase 2 Study of a PrEP Telehealth Intervention
PrEPTECH Phase 2 is a 2-arm randomized controlled trial to assess the effectiveness of a telehealth intervention in increasing PrEP uptake among cisgender men and transgender women who have sex with men over six months.
- Conditions
- Pre-Exposure Prophylaxis, HIV, Telemedicine
- Trial name
- PrEPTECH2 (NCT04902820)
- Testing
- PrEPTECH website, Online PrEP resource list
- Where
- United States
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- ETR Associates
Hiv, Substance Use Disorders
An Intervention to Improve HIV Pre-exposure Prophylaxis Initiation, Adherence and Linkage to Care for Recently Incarcerated Men Who Inject Drugs.
Pre-exposure prophylaxis (PrEP) is effective in preventing HIV infection among people who inject drugs (PWID) yet studies suggest that its use is low among this population which is particularly vulnerable to HIV infection.
- Trial name
- NCT06316089
- Testing
- PrEPared for Release
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Rhode Island Hospital
HIV Infections
A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States
This is a two-arm study evaluating the impact of two implementation strategy conditions, dynamic implementation and routine implementation on the feasibility of delivering of Cabotegravir PrEP in low and high-volume PrEP sites in…
- Trial name
- PILLAR (NCT05374525)
- Testing
- APRETUDE, Cabotegravir OLI
- Where
- 17 sites in United States
- Volunteers
- 287 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
COVID-19, SARS-CoV-2
Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.
- Trial name
- SUPERNOVA (NCT05648110)
- Testing
- AZD5156 (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort)
- Where
- 215 sites in United States, Australia and 16 more
- Volunteers
- 3,882 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hiv
Mhealth for PrEP Adherence by Young Adult MSM, Phase 2
This Phase 2 project aims to enhance and test a mobile health intervention designed to increase adherence to the daily PrEP pill among culturally-diverse young adult men who have sex with men.
- Trial name
- NCT04633200
- Testing
- DOT mobile app
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Environment and Health Group, Inc.
Hiv, Hormone Therapy
Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis
The purpose of this study is to evaluate Pre-Exposure Prophylaxis (PrEP) levels in transgender-identifying or gender non-binary individuals taking versus not taking gender affirming hormone therapy.
- Trial name
- TAF4TRANS (NCT04616963)
- Testing
- Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg, Emtricitabine Tenofovir Alafenamide 200/25 mg
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego